Biotechnology

Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting

November 12, 2021 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / November 12, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced details regarding the presentation of efficacy and safety results for its Phase 1b proof of concept study evaluating a single application of DMT410 to treat multiple aesthetic skin conditions. "A Study of...

Read more

Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

November 12, 2021 8:00 AM

Company advancing XCARTTM pre-clinical development plan toward IND-enabling studies Strengthened cash position to fund operations through XCART IND filing with recently completed $12.5 million private placement Continued royalty stream growth through license agreement with PolyXen® platform technology FRAMINGHAM, MA / ACCESSWIRE / November 12, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical...

Read more

American CryoStem Enters into an Agreement to Exchange Shares held by ACS Global, Inc

November 12, 2021 1:00 AM

EATONTOWN, NJ / ACCESSWIRE / November 12, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a leading strategic cellular application developer, global licensor of patented adipose tissue-based technologies for the Regenerative and Personalized Medicine industries, today announced an agreement has been reached between the Company and ACS Global, Inc to exchange 20,000,000 million CRYO common shares currently held by ACS Global, Inc for...

Read more

Applied UV to Host Third Quarter 2021 Conference Call on November 16th

November 11, 2021 11:35 AM

MOUNT VERNON, NY / ACCESSWIRE / November 11, 2021 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that the Company will be hosting an investor conference call and live webcast...

Read more

Black Bird Biotech Offers Thanks to All Veterans and Their Families

November 11, 2021 10:10 AM

Black Bird Biotech Offers Thanks to All Veterans and Their Families FLOWER MOUND, TX / ACCESSWIRE / November 11, 2021 / Black Bird Biotech, Inc. (OTC PINK:BBBT) released the following statement: On this Veterans Day, the Black Bird Biotech team offers our heart-felt thanks to all of our Great Veterans for their service of our country, and for embodying every quality that makes our country the greatest in human history. We also remember those who...

Read more

Viewpoint Molecular Targeting(R) to Present at the Virtual Investor Roundtable Event

November 11, 2021 10:00 AM

Live moderated video webcast discussion among members of Viewpoint Management and Thought Leaders Oliver Sartor MD, Geoffrey B. Johnson MD, PhD, Vikas Prasad MD, on Thursday, November 18th at 1:00 PM ET CORALVILLE, IA / ACCESSWIRE / November 11, 2021 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic...

Read more

EV Biologics Signs Listing Agreement With INX

November 11, 2021 9:15 AM

NASHVILLE, TN / ACCESSWIRE / November 11, 2021 / EV Biologics Corp, ("the Company"), OTC PINK:YECO, today confirmed that it has signed an agreement to list its common stock on the INX Securities ATS, a regulated alternative trading system operated by INX Securities, LLC. INX Securities, LLC is the FINRA-member broker-dealer subsidiary of INX Limited. The Company has completed its due diligence and has been approved to list on the INX Securities...

Read more

Pressure BioSciences Awarded Second U.S. Patent for Its Revolutionary Ultra Shear Technology Platform, for Its Innovative NanoGap Valve

November 11, 2021 8:10 AM

Dynamically-Adaptive Compact Valve is Key Component in the Company's Highly Anticipated and Proprietary UST Platform; UST Expected to Help Deliver Strong Sales Growth and Profitability in 2022 SOUTH EASTON, MA / ACCESSWIRE / November 11, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialized services to the...

Read more

Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences

November 11, 2021 8:05 AM

BOSTON, MA / ACCESSWIRE / November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences: Jefferies London Healthcare Conference Thursday, November...

Read more

enVVeno Medical Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 11, 2021 8:05 AM

- Quarter marked by corporate rebranding and strategic prioritization of development programs - Company executing on SAVVE U.S pivotal trial evaluating lead product, the VenoValve®, as a potential treatment for severe deep venous Chronic Venous Insufficiency (CVI) - Bolstered cash position with recently completed $20 million registered direct offering with leading life sciences investment firm IRVINE, CA / ACCESSWIRE / November 11, 2021 /...

Read more

Dermata Announces Virtual Investor Event to Present DMT410 Phase 1b Proof of Concept Results in Aesthetic Skin Conditions

November 11, 2021 6:00 AM

SAN DIEGO, CA / ACCESSWIRE / November 11, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it will host a virtual investor event to present the DMT410 Phase 1b results in multiple aesthetic skin conditions on Friday, November 19, 2021 at 4:30 pm ET. The virtual investor event will feature a...

Read more

Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes

November 10, 2021 9:00 AM

KELOWNA, BC / ACCESSWIRE / November 10, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces its plans for several new and ongoing DehydraTECHTM applied R&D programs for 2022. The studies mentioned herein are only a fraction of Lexaria's 2022 work programs. "Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for...

Read more

Black Bird Biotech Provides Corporate Update, Following Completion of Funding Round and Repayment of Convertible Debt

November 10, 2021 8:50 AM

FLOWER MOUND, TX / ACCESSWIRE / November 10, 2021 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, today updated its current status and ongoing progress, following the completion of its current Regulation A funding round. With a portion of the offering proceeds, the company has repaid approximately $700,000 in convertible debt instruments, leaving nearly $1 million available for immediate...

Read more

BioInvent and Transgene present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021

November 9, 2021 8:20 AM

LUND, SE / ACCESSWIRE / November 9, 2021 / BioInvent International (STO:BINV) Data support BT-001's unique dual mode of action BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for...

Read more

RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team

November 9, 2021 6:00 AM

RepliCel's CRO and regulatory advisors now begin preparing Japanese-language documentation to support study clearance VANCOUVER, BC / ACCESSWIRE / November 9, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it's clinical advisory team has completed the primary design of the next-phase...

Read more

Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012

November 8, 2021 8:00 AM

BOSTON, MA and PARIS, FRANCE / ACCESSWIRE / November 8, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, and Servier, a global pharmaceutical group, today announced that the first patient has been dosed in the phase 1/2 study of PRS-344/S095012, a next generation...

Read more

Oncology Pharma Reveals Plans for Development of Lead Cancer Drug Candidate

November 8, 2021 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2021 / Oncology Pharma, Inc. (the "Company") is pleased to provide some insight into the progress of its co-development project with NanoSmart Pharmaceuticals, Inc. for the development of a lead cancer drug candidate. The primary goal of the co-development project is for developing an improved formulation of the cancer drug dactinomycin. Dactinomycin, also known as actinomycin D, is an existing...

Read more

Enzolytics, Inc. Announces Program for Creation of Multiple Monoclonal Antibodies for Veterinary Application Utilizing Hybridoma and Phage Display Technology

November 8, 2021 7:00 AM

COLLEGE STATION, TX / ACCESSWIRE / November 8, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) has announced a coherent protocol that it is executing to meet the Company's objective of producing monoclonal antibodies for veterinary application utilizing Hybridoma and Phage Display Technologies. The Company's defined protocol includes: Application of computer analysis (Artificial Intelligence - A.I.) to curate (analyze) the...

Read more

CORRECTION: Applied UV's Systems Proven to Kill Candida Auris, an Emerging Multi-Drug-Resistant Fungus

November 5, 2021 7:00 AM

The following replaces and corrects the release issued on October 19, 2021: Candida Auris is a pathogenic disease commonly acquired in hospitals or long-term care facilities Centers for Disease Control and Prevention ("CDC") has stated that 30-60% of people with C. auris bloodstream infections die CDC currently considers Candidiasis as one of the most significant infectious diseases in the world today. Currently, there is no vaccine or...

Read more

BioInvent to Show Further Positive BI-1206 Clinical Data in December at ASH 2021

November 4, 2021 9:25 AM

BI-1206 restores rituximab activity in relapsed or refractory patients Demonstrates ORR 50%, DCR 58%, with complete responses lasting beyond 18 and 24 months LUND, SE / ACCESSWIRE / November 4, 2021 / BioInvent International AB ("BioInvent") (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces additional positive interim top-line...

Read more